Kanabolytix is the cannabis testing division of the Toxikon Corporation. Launched in 2017, Kanabolytix draws on Toxikon’s longstanding history and depth of experience in analytical sciences to offer consumers and producers confidence in the safety and efficacy of commercial cannabis products.

Toxikon, founded in 1982, is a preclinical contract research organization (CRO) that provides in vitro, in vivo, and analytical testing services for the pharmaceutical, biotechnology, and medical device sectors. Toxikon is accredited to ISO/IEC 17025, and is registered with the United States Food and Drug Administration and the Japan Ministry of Health, Labor, and Welfare for drug and medical testing.

Toxikon employs hundreds of scientific researchers, associates, laboratory support staff, and others to provide a center of excellence to support product development and testing requirements.

Toxikon currently works globally across the life science sector with over 1,000 active medical device, pharmaceutical, and biologic companies and their suppliers, in over 60 countries.